FTSE 100 today: Index rises, pound strengthens; Tullow Oil slumps, Hiscox rises
Investing.com - Tcr2 Therapeutics reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Tcr2 Therapeutics announced earnings per share of $-0.79 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.78 on revenue of $0.00.
Tcr2 Therapeutics 's are down 35% and is trading at $1.34 , still down 81.79% from its 52 week high of $7.36 set on Wednesday, November 10, 2021.
Tcr2 Therapeutics shares lost 2.90% to trade at $1.34 in intra-day trade the report.
Tcr2 Therapeutics follows other major Healthcare sector earnings this month
Tcr2 Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar